Sign in to continue:

Thursday, March 12th, 2026
us corporate news

LifeMD, Inc. 2025 Annual Report: Virtual Healthcare, Telehealth Growth, and Integrated Pharmacy Platform 101

Posted on March 11, 2026 at 11:28 pm (GMT+8)

35
Views
Share on Facebook
Share on Twitter
  • Company Status and Regulatory Filing:

    • LifeMD is not a well-known seasoned issuer and is not an emerging growth company.
    • It has complied with all SEC filing requirements and submitted all Interactive Data Files as required.
  • Shareholder and Market Information:

    • Common Stock: Par value \$0.01 per share, trading under symbol LFMD on Nasdaq.
    • Preferred Stock: Series A Cumulative Perpetual Preferred Stock (8.875%, par value \$0.0001 per share), trading under symbol LFMDP on Nasdaq.
    • Public Float: \$512,472,017 as of June 30, 2025.
    • Outstanding Shares: 47,973,844 shares as of March 9, 2026.
  • Incorporated Documents:

    • Portions of the 2026 definitive proxy statement, to be filed within 120 days of year-end, are incorporated by reference. This may contain details about board changes, executive compensation, and governance that could affect share value.

    • View LifeMD, Inc. Historical chart here



    Related Posts

    us corporate news

    Pure Storage, Inc. Changes Name to Everpure, Inc.: SEC 8-K Filing Details and Corporate Amendment
    Minichart
    February 24, 2026

    Pure Storage, Inc. - Investor Report Analysis Pur...

    us corporate news

    ADC Therapeutics SA Files 8-K Report Detailing Company Information and Common Shares Listing on NYSE
    Minichart
    March 10, 2026

    ADC Therapeutics SA - 2025 Year-End Financial Results Analys...

    us corporate news

    Tenax Therapeutics, Inc. 2025 Annual Report: Business Strategy, Risk Factors, Clinical Pipeline, and Regulatory Challenges
    Minichart
    March 10, 2026

    Tenax Therapeutics 2025 Annual Report Analysis Tenax T...

       Ad